Olmesartan Medoxomil in Diabetes Mellitus
Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Darmstadt, Germany
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diabetes mellitus type 2, defined as fasting blood glucose of greater than or equal to 126 mg/dL;
Presence of at least one of the following cardiovascular risk factors:
- total cholesterol greater than 200 mg/dL or statin treatment,
- High density lipoprotein (HDL) less than 40 mg/dL,
- triglycerides greater than 150 mg/dL and less than 400 mg/dL,
- blood pressure greater than or equal to 130/80 mmHg,
- Body mass index (BMI) greater than 28 kg/m2,
- waist circumference greater than 102 cm for men and greater than 88 cm for women,
- smoking of more than 5 cigarettes a day;
- Normoalbuminuria at screening
Exclusion Criteria:
- Severe uncontrolled hyperlipidemia;
- Documented renal and/or renal-vascular disease;
- Myocardial infarction, stroke or myocardial revascularization within the last 6 months;
- History of alcohol and/or drug abuse;
- Allergic reaction, lack of response or contraindication to angiotensin receptor blockers (ARBs);
- Current treatment with an ARB or angiotensin converting enzyme (ACE) inhibitor
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: 2
placebo
|
Tablets
|
|
Experimental: 1
olmesartan medoxomil
|
tablets
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time to the first occurrence of microalbuminuria defined as excretion of greater than 35 mg albumin/g urine creatinine for women and greater than 25 mg albumin/g urine creatinine for men in morning spot urine
Time Frame: Time to the first occurrence
|
Time to the first occurrence
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of cardiovascular mortality and morbidity
Time Frame: Time to occurence
|
Time to occurence
|
|
Incidence of renal disease, such as worsening of renal function as well as end-stage (dialysis)
Time Frame: Time to occurrence
|
Time to occurrence
|
|
Occurrence and progression of retinopathy
Time Frame: Time to occurence
|
Time to occurence
|
|
Treatment effects on a combined endpoint of cardiovascular mortality and morbidity and renal disease
Time Frame: Time to occurrence
|
Time to occurrence
|
|
Safety and tolerability
Time Frame: Throughout entire study
|
Throughout entire study
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Prof. Hermann Haller, MD, Medizinische Hochschule Hannover Klinik fur Nieren, Hannover Germany
Publications and helpful links
General Publications
- Chatzikyrkou C, Menne J, Izzo J, Viberti G, Rabelink T, Ruilope LM, Rump C, Mertens PR, Haller H. Predictors for the development of microalbuminuria and interaction with renal function. J Hypertens. 2017 Dec;35(12):2501-2509. doi: 10.1097/HJH.0000000000001491.
- Menne J, Ritz E, Ruilope LM, Chatzikyrkou C, Viberti G, Haller H. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. J Am Heart Assoc. 2014;3(2):e000810. doi: 10.1161/jaha.114.000810.
- Menne J, Izzo JL Jr, Ito S, Januszewicz A, Katayama S, Chatzykirkou C, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, Haller H; ROADMAP investigators. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens. 2012 Apr;30(4):811-8; discussion 818. doi: 10.1097/HJH.0b013e328351856d. Erratum In: J Hypertens. 2012 Aug;30(8):1679.
- Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011 Mar 10;364(10):907-17. doi: 10.1056/NEJMoa1007994.
- Januszewicz A, Ritz E, Viberti G, Mimran A, Rabelink AJ, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL Jr, Haller H. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study). J Hum Hypertens. 2011 Nov;25(11):679-85. doi: 10.1038/jhh.2010.111. Epub 2010 Dec 9.
- Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, Katayama S, Ito S, Mimran A, Menne J, Rump LC, Januszewicz A, Haller H. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia. 2010 Jan;53(1):49-57. doi: 10.1007/s00125-009-1577-3. Epub 2009 Oct 30.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Urologic Diseases
- Endocrine System Diseases
- Cardiovascular Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Kidney Diseases
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Olmesartan
- Olmesartan Medoxomil
Other Study ID Numbers
Other Study ID Numbers
- SE-866/44
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.